证券代码： 300318 证券简称：博晖创新 北京博晖创新光电技术股份有限公司 投资者关系活动记录表 编号： | --- | --- | --- | |----------------|----------------------|-----------------------------------------------------| | | | | | 投资者关系活动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 郝淼 | 宝盈基金管理有限公司 | | 人员姓名 | 段鹏程 | 宝盈基金管理有限公司 | | | | | | | 田加强 | 中信证券股份有限公司 | | | | 魏卓 华银基金管理有限公司 | | 时间 | 2016 年 3 月 | 日星期三： 09:30 – 10:30 | | 地点 | | 北京博晖创新光电技术股份有限公司会议室 | | 上市公司接待人 | 董事会秘书 刘敏 | | ...

证券代码： 300318 证券简称：博晖创新 北京博晖创新光电技术股份有限公司 投资者关系活动记录表 编号： | --- | --- | --- | |------------|----------------|-------------------------------------| | | | | | 投资者关系 | √ 特定对象调研 | □ 分析师会议 | | 活动类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名 | 胡偌碧 | 东兴证券股份有限公司 | | 称及人员姓 | 张文录 | 华创证券有限责任公司 | | 名 | | 张晓 华商基金管理有限公司研究发展部 | | | 陈洁馨 | 建信基金管理公司研究部 | | | 范强旺 | 中海基金管理有限公司投研中心 | | | 牟彩萍 | 北京源乐晟资产管理有限公司 | | | 祝佳婧 | 中再资产管理股份有限公司 | | | 李嘉永 | 北京立名投资管理有限公司 | | | 杨珊 和君资本 | | | | | ...

Group 1: Company Strategy and Development - The company will continue to focus on its core business areas (IVD and biological products) and enhance user satisfaction while increasing investment in new product development over the next two to three years [2][3] - The company aims to accelerate research and development in the health sector, particularly in IVD, and expand its product line and application areas in analytical instruments [3][4] - The company has completed strategic layouts in inspection, biological products, and research equipment, and plans to further develop products and integrate business operations in these areas over the next three to five years [3][4] Group 2: Financial Performance and Challenges - The management is committed to improving company performance and addressing the pressure on earnings through diligent management practices [3][4] - The company has faced challenges due to rising raw material prices but plans to mitigate these impacts through production line upgrades and supply chain management [5][6] - The company has experienced continuous losses in recent years but is focused on developing new technologies and products to enhance market share and core competitiveness [5][6] Group 3: Product Development and Market Position - The company has invested significantly in the development of blood products, with two subsidiaries now producing seven types of blood products, covering important varieties in the market [5][6] - A new blood product production base with a capacity of 1,500 tons is under construction, which will significantly enhance production capabilities and technical levels [5][6] - The company is actively exploring international markets for its COVID-19 testing kits, having obtained CE certification for its products [4][5] Group 4: Corporate Governance and Investor Relations - Shareholder stock reductions are based on personal decisions and do not reflect concerns about the company's future [6][7] - The company emphasizes compliance with regulations and has taken steps to educate management on legal responsibilities following incidents of stock reduction by executives [6][7] - The company is open to hosting investor visits to enhance understanding and gather constructive feedback [7][8]

证券代码： 300318 证券简称：博晖创新 北京博晖创新生物技术集团股份有限公司 投资者关系活动记录表 编号：2022-01 | --- | --- | --- | --- | --- | |---------------------|--------------------------------------|----------------------------------------------------------|-------|----------------------| | | | | | | | 投资者关系 活动类别 | □ 特定对象调研 □ 媒体采访 | □ 分析师会议 √ 业绩说明会 | | | | | □ 新闻发布会 | □ 路演活动 | | | | | □ 现场参观 | | | | | | □ 其他 | | | | | 参与单位名 | | | | | | 称及人员姓 | 参与博晖创新 2021 | 年度网上业绩说明会的投资者 | | | | 名 | | | | | | 时间 | 2022 年 5 月 7 日星期六： | 15:00 – 17:00 | | | | 地点 | | ...

北京博晖创新生物技术集团股份有限公司 2022 年第三季度报告 证券代码：300318 证券简称：博晖创新 公告编号：临 2022-043 北京博晖创新生物技术集团股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、完 整。 3.第三季度报告是否经过审计 □是 否 1 北京博晖创新生物技术集团股份有限公司 2022 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入（元） | 214,100,881.83 | 16.79% | 597,413,453.96 | 12.29% | | 归属于上市公司股东 | -19,539,556.10 ...

北京博晖创新生物技术集团股份有限公司 2022 年半年度报告全文 北京博晖创新生物技术集团股份有限公司 2022 年半年度报告 定 2022-03 2022 年 8 月 1 北京博晖创新生物技术集团股份有限公司 2022 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及除以下存在异议声明的董事、监事、高级管理人员 外的其他董事、监事、高级管理人员均保证半年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责 任。 董事、监事、高级管理人员异议声明 | 姓名 | | 职务 | | 内容和原因 | | --- | --- | --- | --- | --- | | 无 | 无 | | 无 | | 无 公司负责人沈治卫、主管会计工作负责人董海锋及会计机构负责人(会计 主管人员)陈思绪声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本半年度报告内容中涉及的未来计划等前瞻性陈述因存在不确定性，不构 成公司对投资者的实质承诺，请投资者注意投资风险。公司不存在因经营状 况、财务状况和持续盈利能力方面有严重不利影响 ...

Revenue and Profitability - The company's revenue for Q1 2022 was CNY 175,394,242.89, representing a 10.23% increase compared to CNY 159,118,438.30 in the same period last year[4] - The net profit attributable to shareholders was a loss of CNY 13,243,101.60, which is a 26.47% increase in loss compared to a loss of CNY 10,471,465.66 in the previous year[4] - The net profit for the current period is a loss of $26,680,596.65, compared to a loss of $21,160,208.78 in the previous period, reflecting a deterioration of approximately 26%[26] - The total comprehensive loss for the current period is $26,934,387.20, compared to a loss of $20,954,032.52 in the previous period, indicating an increase in losses of about 28.5%[26] Cash Flow and Operating Activities - The net cash flow from operating activities was a negative CNY 29,404,292.88, a decline of 138.79% from a negative CNY 12,313,915.41 in the same period last year[4] - The cash flow from operating activities shows a net outflow of $29,404,292.88, worsening from a net outflow of $12,313,915.41 in the previous period[28] - The company reported a cash inflow from financing activities of $132,357,092.92, compared to $127,719,272.37 in the previous period, showing a slight increase of about 3.5%[29] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,768,492,715.30, an increase of 2.13% from CNY 3,690,026,740.04 at the end of the previous year[5] - The total assets of Beijing Bohui Innovation Biotechnology Group Co., Ltd. as of March 31, 2022, amounted to CNY 3,768,492,715.30, an increase from CNY 3,690,026,740.04 at the beginning of the year[22] - Total liabilities rose to CNY 2,862,682,069.22 from CNY 2,757,281,706.76, an increase of about 3.8%[22] - The company's total equity decreased to CNY 905,810,646.08 from CNY 932,745,033.28, a decline of approximately 2.9%[22] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 50,030, with the largest shareholder holding 39.03% of the shares[13] Financial Ratios and Performance Metrics - The weighted average return on net assets was -1.37%, a decrease of 40.88% compared to -0.81% in the previous year[5] - Basic and diluted earnings per share for the current period are both -$0.0162, compared to -$0.0128 in the previous period, reflecting a decline in earnings[26] Expenses - The company reported a 68.18% increase in financial expenses, amounting to an increase of CNY 5,093,400, primarily due to increased interest-bearing liabilities to support project construction[9] - Total operating costs for the current period are $200,887,913.43, up from $177,047,246.72 in the previous period, indicating an increase of about 13.4%[25] - Research and development expenses for the current period are $13,783,836.86, down from $15,815,565.02 in the previous period, indicating a decrease of approximately 12.9%[25] Cash and Equivalents - The company's cash and cash equivalents increased to CNY 103,472,840.41 from CNY 39,394,993.04, representing a growth of approximately 163.5%[19] - Cash and cash equivalents at the end of the period amount to $99,811,835.38, an increase from $73,949,719.56 at the end of the previous period, representing a growth of about 35%[29] Inventory and Receivables - Accounts receivable decreased to CNY 88,325,335.14 from CNY 92,107,187.76, a decline of about 4.2%[19] - Inventory increased slightly to CNY 832,530,828.17 from CNY 820,953,599.87, reflecting a growth of approximately 1.7%[19] Non-Current Assets - The company’s non-current assets totaled CNY 2,610,191,804.91, showing a slight decrease from CNY 2,610,465,600.84[22] Short-Term Borrowings - The company’s short-term borrowings increased to CNY 438,304,359.67 from CNY 434,893,006.77, a rise of approximately 0.9%[22] Audit Status - The company has not undergone an audit for the first quarter report[30]

Financial Performance - The company reported a significant loss during the reporting period, primarily due to the suspension and renovation of its subsidiary, Zhongke Biological, leading to a substantial decline in revenue[5]. - The loss was exacerbated by increased external debt and financial expenses to support the construction of the blood product production base in Qujing, Yunnan[5]. - The company's operating revenue for 2021 was ¥714,748,462.45, a decrease of 3.24% compared to ¥738,717,388.06 in 2020[23]. - The net profit attributable to shareholders was -¥322,176,629.03, representing a significant decline of 4,393.41% from a profit of ¥7,503,976.45 in 2020[23]. - The net cash flow from operating activities was ¥887,777.88, down 98.97% from ¥86,137,577.29 in the previous year[23]. - The total assets at the end of 2021 amounted to ¥3,690,026,740.04, a slight decrease of 0.68% from ¥3,715,242,196.65 at the end of 2020[23]. - The net assets attributable to shareholders decreased by 25.02% to ¥974,752,736.01 from ¥1,299,959,538.30 in 2020[23]. - The company reported a basic and diluted earnings per share of -¥0.3944, a decline of 4,386.96% from ¥0.0092 in 2020[23]. - The company’s revenue from core business after deductions was ¥682,179,143.93, down from ¥723,174,605.61 in 2020[23]. - The company’s quarterly revenue showed a decline in the fourth quarter, with a revenue of ¥182,736,686.27 compared to previous quarters[25]. Research and Development - The company has increased its R&D expenditure, indicating a commitment to innovation despite the financial challenges faced[5]. - R&D expenses surged by 69.13% to ¥81.48 million in 2021, reflecting the company's intensified investment in new product development[89]. - R&D investment amounted to ¥90.91 million in 2021, representing 12.72% of operating revenue, up from 10.31% in 2020[92]. - The number of R&D personnel increased by 26.47% to 129 in 2021, with a notable rise in the number of PhD holders from 7 to 15[91]. - The company is developing a fully automated real-time fluorescence nucleic acid detection system, which is expected to enhance market competitiveness upon product registration[90]. - The company aims to achieve product registration for various new products, which will enhance its competitive position in the industry and improve economic benefits[90]. Market and Industry Outlook - The company operates in the in-vitro diagnostics (IVD) sector, which is projected to grow from a market size of $67.11 billion in 2019 to $91.09 billion by 2027, with a CAGR of 4.8%[34]. - The Chinese in vitro diagnostic market is projected to reach ¥288.15 billion by 2030, becoming the largest consumer of in vitro diagnostic products globally[35]. - The blood products industry in China has 28 licensed manufacturers, with a total plasma collection of approximately 9,400 tons in 2021, reflecting a 13% increase from 2020[45]. - The demand for blood products in China exceeds 14,000 tons, indicating a significant supply-demand gap in the market[43]. - The company is focused on expanding its product line with various calibration solutions for blood and serum testing, set for registration renewal in January 2026[55]. Product Development and Sales - The company is set to launch a series of new diagnostic kits, including a combined test kit for rotavirus and enteric adenovirus, expected to be available by January 2024[54]. - A new atomic absorption spectrometer will be introduced in February 2023, designed for measuring lead and cadmium levels in human blood[54]. - The company plans to release multiple atomic absorption spectrometers by April 2024, which will measure various elements including copper, zinc, calcium, magnesium, and iron in human blood[54]. - The company’s blood products are primarily sourced from its plasma collection stations, which are regulated and licensed by provincial health authorities[61]. - The company’s biological products are subject to batch release management, ensuring quality control before market entry[61]. Operational Challenges and Risks - The management has indicated that the current losses are not sustainable and that there are no significant risks to the company's ongoing operations[5]. - Future plans and forward-looking statements in the report carry uncertainties and do not constitute a substantive commitment to investors[5]. - The company is actively addressing potential operational risks and has outlined corresponding measures in the management discussion section of the report[5]. - The company faces operational risks due to the recurring impacts of the COVID-19 pandemic on supply chains and sales[130]. Governance and Management - The board of directors consists of 7 members, including 3 independent directors, who actively participate in training and fulfill their duties according to regulations[146]. - The company has a total of 3 supervisors in the supervisory board, ensuring compliance and legality in the performance of duties by directors and senior management[147]. - The company maintains independence in personnel, assets, finance, institutions, and business from the controlling shareholder, ensuring autonomous operation[153]. - The company has established a good interactive relationship with investors, adhering to investor relations management regulations[151]. - The company has a structured decision-making process for determining the remuneration of directors and senior management, involving the nomination and compensation committee[177]. Future Outlook - The company has provided a positive outlook for 2022, projecting a revenue growth of 10% to 1.32 billion RMB[56]. - The company aims to enhance its international presence, with plans to enter two new overseas markets by the end of 2022[56]. - The company has set a future outlook with a revenue target of 1.5 billion yuan for the next fiscal year, indicating a projected growth rate of 25%[171]. - The company plans to enhance its digital marketing strategy, allocating an additional 30 million yuan to increase brand awareness and customer engagement[171].

Financial Performance - The company's operating revenue for Q3 2021 was ¥183,324,389.65, a decrease of 19.58% compared to the same period last year[3]. - The net profit attributable to shareholders was -¥12,079,885.78, reflecting a decline of 155.81% year-on-year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥12,419,578.55, a decrease of 161.51% compared to the previous year[3]. - The net profit for Q3 2021 was -76,486,558.47 CNY, compared to a net profit of 4,464,776.70 CNY in the same period last year, indicating a significant decline[33]. - The company reported a total comprehensive loss of -76,612,587.69 CNY for the quarter, compared to a comprehensive income of 3,114,472.97 CNY in the same quarter last year[33]. - The company incurred a total operating profit loss of -68,933,560.22 CNY, compared to an operating profit of 12,151,237.64 CNY in the previous year[33]. - The basic and diluted earnings per share were both -0.0345 CNY, compared to 0.0070 CNY in the same period last year[34]. Assets and Liabilities - The total assets at the end of the reporting period were ¥3,940,276,505.70, an increase of 6.06% from the end of the previous year[3]. - The total liabilities of the company as of September 30, 2021, were CNY 2,577,984,214.59, up from CNY 2,276,337,317.85, reflecting an increase of about 13.23%[30]. - The company's cash and cash equivalents stood at CNY 47,900,709.92 as of September 30, 2021, compared to CNY 44,595,499.31 at the end of 2020[28]. - The cash and cash equivalents at the end of the period were 46,488,862.00 CNY, down from 140,246,199.64 CNY at the end of the previous year[37]. - Accounts receivable decreased to CNY 115,159,768.63 from CNY 148,456,370.17, a decline of about 22.39%[28]. - Inventory increased to CNY 811,353,650.76 from CNY 789,549,320.61, showing a growth of approximately 2.43%[29]. Cash Flow - The company's cash flow from operating activities showed a net outflow of -¥3,284,164.08, a decline of 104.74% year-to-date[3]. - The cash flow from operating activities showed a net outflow of -3,284,164.08 CNY, contrasting with a net inflow of 69,307,518.34 CNY in the previous year[36]. - The total cash inflow from financing activities was 1,273,781,564.69 CNY, while the cash outflow was 957,135,273.57 CNY, resulting in a net cash inflow of 316,646,291.12 CNY[37]. Expenses - Research and development expenses for the year-to-date reached ¥49,792,900, an increase of 51.16% compared to the same period last year[11]. - Management expenses for the year-to-date totaled ¥129,632,100, an increase of 76.70% year-on-year[11]. - The company's cash paid for purchasing goods and services was ¥248,198,900, an increase of 39.76% compared to the previous year[15]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 54,539[19]. - The largest shareholder, Du Jiangtao, holds 39.03% of the shares, totaling 318,811,388 shares, with 12,000,000 shares pledged[19]. - The company’s management has 20,419,006 restricted shares, which are subject to a 25% release each year on the first trading day[22]. - There are no preferred shareholders or changes in restricted shares reported for the period[21]. Regulatory and Compliance - The company plans to enhance compliance training for its executives to prevent future regulatory violations following a recent incident involving stock sales by a senior executive[26]. - The board of directors is committed to strengthening adherence to relevant laws and regulations to avoid similar incidents in the future[26]. Other Information - The company reported a decrease in cash received from other operating activities by 42.55% year-to-date, totaling ¥22,508,400[14]. - Cash used for debt repayment from the beginning of the year to the end of the reporting period was CNY 537.98 million, a decrease of 33.36% compared to the same period last year, due to a reduction in bank loan repayments[17]. - Cash paid for other financing activities amounted to CNY 399.50 million, a decrease of 67.72% year-on-year, attributed to a reduction in related party transactions[17]. - The impact of exchange rate fluctuations on cash and cash equivalents was -CNY 159,600, an increase of 74.90% compared to the same period last year, mainly due to foreign currency translation[17]. - The company reported a decrease in other comprehensive income, with a total of -126,029.22 CNY for the quarter, compared to -1,350,303.73 CNY in the same period last year[33]. - The company did not report any net profit from subsidiaries prior to the merger during the period[34]. - The company has completed the extended audit work for a transaction and applied to resume the review of the application documents on August 4, 2021[24]. - The company terminated the issuance of shares to purchase assets and related fundraising on September 6, 2021[24].

北京博晖创新生物技术集团股份有限公司 2021 年半年度报告全文 北京博晖创新生物技术集团股份有限公司 2021 年半年度报告 定 2021-04 2021 年 08 月 1 北京博晖创新生物技术集团股份有限公司 2021 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司负责人翟晓枫、主管会计工作负责人董海锋及会计机构负责人(会计主 管人员)李娟声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本半年度报告内容中涉及的未来计划等前瞻性陈述因存在不确定性，不构 成公司对投资者的实质承诺，请投资者注意投资风险。公司不存在因经营状况、 财务状况和持续盈利能力方面有严重不利影响的风险因素。有关公司可能面对 的风险及公司应对措施等详见本报告第三节"管理层讨论与分析"中相关内容。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 第一节 | 重要提示、目录和释义 | 错误！未定义书签。 | | --- ...